Found: 6
Select item for more details and to access through your institution.
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 68, doi. 10.1007/s10637-021-01156-9
- By:
- Publication type:
- Article
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 3, p. 803, doi. 10.1007/s10637-020-01047-5
- By:
- Publication type:
- Article
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 9, p. 1935, doi. 10.1111/bcp.13974
- By:
- Publication type:
- Article
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 7, p. 1495, doi. 10.1111/bcp.13920
- By:
- Publication type:
- Article
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 3, p. 239, doi. 10.1007/s00280-023-04510-1
- By:
- Publication type:
- Article
Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 6, p. 997, doi. 10.1007/s00280-021-04353-8
- By:
- Publication type:
- Article